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OBJECTIVE: To assess relative success rates and re-
source utilization differences between males and females
treated to NCEP and EAS cholesterol goals with HMG-
CoA reductase inhibitors. METHODS: In three open-
label clinical trials in the US and Europe, 998 patients (375
females and 623 males) with a CHD risk factor, docu-
mented CHD and/or PVD, were randomized to receive
one of five HMG-CoA reductase inhibitors (atorvastatin,
fluvastatin, lovastatin, pravastatin, or simvastatin). Phy-
sician visits occurred every 6 weeks and dose titrations
(either increased statin dose, or the addition of colestipol
or cholestyramine) were made every 12 weeks if target
LDL-C concentration levels were not achieved. The anal-
ysis takes a third party perspective by using insurance
payment rates for study medications, physician visits,
add-on therapies and treatments for adverse events, all
denominated in 1997 US dollars. RESULTS: NCEP or
EAS LDL-C targets were achieved with similar frequency
by males (75.7%) and females (74.7%). Accordingly, re-
source utilization was similar for males and females.
Mean total costs were similar for all males ($1529.94)
and females ($1470.99, p  0.776); males ($1280.62)
and females ($1252.95, p  0.665) reaching goal and
males ($2306.32) and females ($2115.59, p  0.103) not
reaching goal. Finally, mean total costs for males and fe-
males (and respective percentages achieving LDL-C tar-
gets) were similar among study medications: atorvastatin
$1044.49 (88.2%) and $1020.29 (90.7%); fluvastatin
$1815.03 (58.4%) and $1709.72 (55.5%); lovastatin
$2031.78 (77.9%) and $2045.43 (80.3%); pravastatin
$1878.90 (53.6%) and $1776.19 (35.7%) and simvasta-
tin $1475.48 (80.3%) and $1293.43 (77.0%). CON-
CLUSIONS: Successes in achieving LDL-C targets and
resource utilization were independent of gender. How-
ever the ability to reach target LDL-C, by use of specific
study medications, significantly impacts the total cost of
cholesterol reduction.
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Considerable clinical trial data is available to support the
use of beta-blockers for the treatment of congestive heart
failure (CHF). OBJECTIVES: The primary objective is to
compare differences in health care costs (pharmacy, med-
ical, and total) between patients receiving carvedilol and
those not receiving a beta-blocker for the treatment of
CHF. The secondary objective is to determine differences
among cohorts with respect to CHF-related costs and
total health care costs (CHF and non-CHF related).
METHODS: Retrospective claims data from a large man-
aged care organization were analyzed. Patients were in-
cluded if they had an ICD-9 diagnosis code for CHF be-
tween 1/1/97 and 12/31/99, received an ACE inhibitor
and a diuretic, were continuously eligible, and at least 18
years old. The carvedilol group was newly started on
carvedilol and did not receive another beta-blocker. The
non beta-blocker group did not receive any beta-blockers
and had no contraindications to beta-blocker therapy. All
patients were followed for 1 year. Total health care costs
include costs for all services covered. CHF-related costs
include those directly related to the treatment of CHF.
RESULTS: There were a total of 9,439 patients, 52.3%
were female, and the average age was 77 (S.D.  9.5)
years. Total cost (CHF and non-CHF related) were mea-
sured after adjusting for age, gender, pre-total cost, and
Charlson Comorbidity Index. Patients in the carvedilol
group had higher pharmacy cost ($2,586 versus $1,343,
P  .0001), lower medical cost ($18,196 versus $22,168,
P  0.362), and lower total cost ($20,782 versus
$23,511, P  0.619). When measuring only CHF-related
costs, patients in the carvedilol group had higher phar-
macy cost ($1,489 versus $416, P  .0001), lower medi-
cal cost ($2,232 versus $3,105, P  0.450), and slightly
higher total cost ($3,721 versus $3,521, P  0.959).
CONCLUSION: The higher pharmacy cost of carvedilol
use appears to be offset by a reduction in total (CHF and
non-CHF related) medical cost.
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OBJECTIVE: To conduct a cost-effectiveness analysis of
tissue-Plasminogen Activator (t-PA) versus Streptokinase
(SK) for treating acute myocardial infarction (AMI). PER-
SPECTIVE: Societal. DATA SOURCES: The cost, clini-
cal outcomes and utilities were obtained from literature.
METHODS: Decision analytical model was used to eval-
uate the short and long-term outcomes and costs associ-
ated with the use of SK or t-PA for AMI. Clinical benefit
is expressed as Quality Adjusted Life Years (QALY) re-
sulting from the treatment. Patients presenting within six
hours after onset of symptoms, with a certain probability
of death may be treated with SK or t-PA. Survivors may
either get a disabling stroke or no stroke, patients with
no disabling stroke may or may not have a reinfarction.
Inpatient and long-term costs of coronary disease and
disabling stroke were included. Costs and QALYs were
discounted at 3%. Expected costs and QALYs yielded the
Incremental Cost-effectiveness Ratio (ICER). Sensitivity
analyses were performed on important factors. OUT-
COMES: QALY which incorporated 30 days mortality,
impacts of disabling stroke, reinfarction. Short-term and
